With more than 1,100 projects completed across most therapeutic areas, Novotech has a world of experience. And it’s that experience that sets us apart, making us one of the leading midsize clinical research organizations – not just in the Asia-Pacific region, but in the world.
Phase I study helps company secure second indication for lead product with Healthy volunteer study in Australia
Early clinical-stage US biotech DiaMedica engaged Novotech to provide CRO services and help it take advantage of Australia’s supportive early stage research environment and the country’s rapid regulatory processes.
Biotechnology company looking for Oncology CRO services. Regulatory and recruitment expertise expedites clinical trial timelines for Oncology clinical study.
When South Korean oncology biotechnology company PharmAbcine completed a successful domestic phase I study for the treatment of metastatic/refractory solid tumor, they were keen to progress into a phase II study.
Biotechnology company looking for Cardiovascular CRO services. Trial monitoring helps change cardiology standard of care in Australia
As part of a global registry study, the Thrombosis Research Institute (TRI) engaged Novotech to monitor a registry across Australia, investigating the treatment of atrial fibrillation patients through to routine standard of care. Key to success was Novotech’s ability identifying appropriate sites and strong relationships with Principal Investigators (PIs) and provide Cardiovascular CRO services.
Rescue study and Oncology CRO services. Local know-how gets pivotal breast cancer trial back on track
When recruitment for a global breast cancer trial was lagging, Novotech was engaged as the Asia Pacific regional CRO to help bring the project back on track.
Providing Dermatology CRO services. Helping an acne trial overcome recruitment challenges
Early clinical-stage US dermatology biotech Botanix Pharmaceuticals was keen to accelerate the clinical development of its dermatology lead acne product and looked to the Asia-Pacific region to take advantage of the Australia’s supportive regulatory environment and R&D tax rebate scheme and vast patient pool.
Providing Infectious disease CRO services. Key Asia Pacific recruitment for global phase III lung disease trial.
As part of its global phase III trial, a US biotechnology company required the inclusion of specific Asia Pacific countries due to the high prevalence of mycobacterium avium complex (MAC) in these countries.
Providing Gastrointestinal CRO services and Metabolic diseases CRO services. Integrated approach achieves early DBL for an adaptive design endocrinology trial
Novotech was engaged as a full-service CRO in a multicenter phase I/II obesity treatment research program. Despite multiple challenges, The Novotech clinical, regulatory, data management and biometrics experts achieved key study milestones ahead of schedule.